IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age, Version 1.0
This Study is
No Longer Enrolling
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 18-2714
More information available at ClinicalTrials.gov: NCT03760458
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers